DWTX - Dogwood Therapeutics EV/EBITDA Multiple

Corporate company logo of Dogwood Therapeutics Inc. (DWTX)

This EV/EBITDA price action chart, which stands at 0.00, serves as confirmation of the market valuation and illustrates the value of Dogwood Therapeutics, Inc. (DWTX). The business relies on unique patents and strict FDA control. The environmental strategy is based on minimizing waste during drug synthesis. Stability is ensured by retaining the core research staff and hiring specialized compliance experts.

DWTX Virios Therapeutics: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/18/2026

Analytical breakdowns for Dogwood Therapeutics, Inc.

- stock price and consensus target price:
Fundamental company valuation:DWTX (Virios Therapeutics)
Original product of dwtx.com

Dogwood Therapeutics, Inc. (DWTX) is developing a scalable antiviral production model utilizing a system of external contractors and CMOs. The EV/EBITDA multiple allows for a correlation between the total enterprise value, including debt load, and its actual operational efficiency. This metric determines the company's ability to service its obligations, signaling an overvaluation during sharp increases or a hidden liquidity deficit in the event of an anomalous undervaluation.

Competitor analysis

Gilead Sciences, Inc. - Enterprise Value to EBITDA Ratio|Cidara Therapeutics, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CureVac NV CVAC|Valneva Pharma (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Corp (VIR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio SIGA|Emergent BioSolutions (EBS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharma (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio Invivyd|EV/EBITDA Multiple ENTA (enanta.com)|INO: Enterprise Value to Operating Income Before Depreciation|hillevax.com - EV/EBITDA Multiple|KLRS - EV/EBITDA Multiple|DYAI: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation NNVC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Talphera|COCP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Traws Therapeutics (TRAW)|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Therapeutics|EV/EBITDA Multiple ALVR (allovir.com)|EV/EBITDA Multiple VBI Vaccines Inc VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (vaxart.com)